



*Supplementary Material*



**Supplementary Figure 1.** Relationship between the occurrence of CRS/CRES and expansion of CART cells in vivo.



**Supplementary Figure 2.** Analysis of risk factors related to the occurrence of CRS/CRES. The relationship between the occurrence of CRS/CRES and the peak serum concentration of IL-6 and CRP, the concentration of LDH before infusion (A), the infusion dose of CART cells, and the highest level of CART cell expansion in vivo (B).

**Supplementary Table 1.** 4SCAR19 T cell dose administered.

	<b>Patients (N=21)</b>
CAR-positive viable T-cell dose infused ( $10^5$ cells/kg)	
Mean (SD)	13.08 (12.89)
Median	8.87
Range	0.28~47.96
Total cell dose infused ( $10^6$ cells/kg)	
Mean (SD)	2.75 (1.48)
Median	2.47
Range	0.39~7.44

**Supplementary Table 2.** Differences in remission time after infusion in patients with complete remission and partial remission.

<b>Efficacy</b>	<b>Time post-infusion/days</b>		<b>Statistic</b>	<b>Sig.</b>
<b>CR</b>	Mean		49.78	0.509
	95% CI for Mean	Lower Bound	41.31	
		Upper Bound	58.25	
	Median		54	
	Std. Deviation		11.020	
	Minimum		34	
Maximum		63		
<b>PR</b>	Mean		55.00	
	95% CI for Mean	Lower Bound	36.90	
		Upper Bound	73.10	
	Median		61	
	Std. Deviation		14.577	
	Minimum		29	
Maximum		63		

**Supplementary Table 3.** Prolonged cytopenias in all patients in the study.

<b>Prolonged Cytopenias, %</b>	<b>Patients (N=21)</b>		
	at any time	at $\geq$ 28 days	at $\geq$ 3 months
<b>Neutropenia <math>\geq</math> grade 3</b>	76%	29%	14%
<b>Anemia <math>\geq</math> grade 3</b>	24%	14%	0%
<b>Thrombocytopenia <math>\geq</math> grade 3</b>	29%	29%	10%